These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19401796)

  • 61. Rapid DNA extraction protocol for detection of alpha-1 antitrypsin deficiency from dried blood spots by real-time PCR.
    Struniawski R; Szpechcinski A; Poplawska B; Skronski M; Chorostowska-Wynimko J
    Adv Exp Med Biol; 2013; 756():29-37. PubMed ID: 22836616
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
    Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
    [TBL] [Abstract][Full Text] [Related]  

  • 63. alpha1-Antitrypsin deficiency: best clinical practice.
    Kalsheker NA
    J Clin Pathol; 2009 Oct; 62(10):865-9. PubMed ID: 19783716
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.
    Dickens JA; Lomas DA
    Drug Des Devel Ther; 2011; 5():391-405. PubMed ID: 21966212
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.
    Barros-Tizón JC; Torres ML; Blanco I; Martínez MT;
    Ther Adv Respir Dis; 2012 Apr; 6(2):67-78. PubMed ID: 22354900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alpha 1-antitrypsin deficiency: an overview.
    van Steenbergen W
    Acta Clin Belg; 1993; 48(3):171-89. PubMed ID: 8396299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.
    Chapman KR; Stockley RA; Dawkins C; Wilkes MM; Navickis RJ
    COPD; 2009 Jun; 6(3):177-84. PubMed ID: 19811373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
    Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
    Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alpha-1 Antitrypsin Deficiency: Beyond the Protease/Antiprotease Paradigm.
    Cosio MG; Bazzan E; Rigobello C; Tinè M; Turato G; Baraldo S; Saetta M
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S305-10. PubMed ID: 27564665
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Longterm Homecare Augmentation Program in Alpha-1-Antitrypsin Deficient Patients].
    Wilke A; Semper H; Gross C; Grohé C
    Pneumologie; 2018 Aug; 72(8):590-597. PubMed ID: 30089330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. α1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population.
    Bornhorst JA; Greene DN; Ashwood ER; Grenache DG
    Chest; 2013 Apr; 143(4):1000-1008. PubMed ID: 23632999
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alpha-1-antitrypsin replacement therapy: current status.
    Abusriwil H; Stockley RA
    Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Measuring and Interpreting Serum AAT Concentration.
    Donato LJ; Snyder MR; Greene DN
    Methods Mol Biol; 2017; 1639():21-32. PubMed ID: 28752443
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incidence of alpha-1 antitrypsin Z and S alleles in patients with granulomatosis with polyangiitis--pilot study.
    Chorostowska-Wynimko J; Gawryluk D; Struniawski R; Popławska B; Fijołek J
    Pneumonol Alergol Pol; 2013; 81(4):319-22. PubMed ID: 23744167
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Key current clinical issues in alpha-1 antitrypsin deficiency.
    Stoller JK
    Respir Care; 2003 Dec; 48(12):1216-21; discussion 1221-4. PubMed ID: 14651762
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.
    Teckman JH
    COPD; 2013 Mar; 10 Suppl 1():35-43. PubMed ID: 23527737
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of alpha-1 antitrypsin in human health and disease.
    de Serres F; Blanco I
    J Intern Med; 2014 Oct; 276(4):311-35. PubMed ID: 24661570
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].
    Wencker M
    Med Klin (Munich); 1999 Mar; 94(3):137-9. PubMed ID: 10218347
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency].
    Miravitlles M; Vidal R; Torrella M; Bofill JM; Cotrina M; de Gracia J
    Arch Bronconeumol; 1994 Dec; 30(10):479-84. PubMed ID: 7827760
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
    Wencker M; Fuhrmann B; Banik N; Konietzko N;
    Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.